Hallura Overview
Hallura is building a new technology platform for the creation of the next generation of dermal fillers for aesthetic medicine. Designed to overcome the limitations of current products, Halluras HA Dermal Fillers are answering the growing demand for soft, natural, noninvasive aesthetic treatments. The companys products are based on its proprietary cross-linking technology, which uses a novel cross-linking mechanism to maintain and protect natural HA long chains. Hallura has completed a full set of in vivo animal studies of its products, demonstrating excellent safety and a higher potential for skin lifting compared with other leading products currently on the market.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
"Click Chemistry" Concept Inspires BiOLinkMatrix by HALLURA™: the Next Generation of HA Dermal Fillers
Hallura Ltd., an Israeli aesthetic medical company, has announced the development of its proprietary technology, the BiOLinkMatrix platform, which revolutionizes the way Hyaluronic Acid (HA) is cross-linked in dermal fillers. The technology is inspired by the 2022 Nobel Prize for Click Chemistry, awarded to K. Barry Sharpless, Morten Meldal, and Carolyn R. Bertozzi. Halluras advanced product line includes treatments for skin rejuvenation, fine and deep lines smoothing, and volume restoration in lips and mid-face. The company attributes the exceptional safety and natural outcomes of its products to the use of bio-orthogonal chemistry. Halluras HA dermal fillers aim to provide better, safer fillers with natural and soft aesthetic results.
Partners
growth-positive
Hallura Announces Successful Topline Results of European Multi-Site Clinical Trial with its New BiOLinkMatrix HA Aesthetic Dermal Fillers
Hallura Ltd., an Israeli aesthetic medical company, announced successful topline results from its European clinical trial for its next generation Hyaluronic Acid (HA) Dermal Fillers. The trial evaluated the safety and effectiveness of three BiOLinkMatrix gels using different HA concentrations for lips enhancement, nasolabial folds correction, and cheeks enhancement. The study met its primary performance endpoint and demonstrated improvement in aesthetic appearance in all three indications. The treatment effectiveness was sustained in most subjects, and a positive safety profile was shown. The company aims to submit for regulatory approval in key territories after completing the 12-month patient follow-up.
Customers
growth-positive
Hallura Announces the Appointment of Paul Navarre to Its Board of Directors
Hallura Ltd., an Israeli aesthetic medical company, has appointed Paul Navarre as an independent director of its Board of Directors. Navarre has over 25 years of experience in the pharmaceuticals and consumer goods industries, having served as CEO of Ferring Holding Inc (US) and President of Allergan International. Hallura, which was founded in 2017, is developing the next generation of Hyaluronic Acid (HA) Dermal Fillers.
Management Changes
growth-positive
Israel dermal filler co Hallura raises $7m
Israeli aesthetic medical company Hallura has closed a $7 million Series A financing round led by a group of private investors, including leading plastic surgeons and dermatologists. The company, founded in 2017, has developed a new generation of Hyaluronic Acid (HA) Dermal Fillers using a novel crosslinking technology. The technology aims to meet the growing demand for natural and soft non-invasive aesthetic treatments. Halluras products have shown excellent safety and potential for skin lifting in animal studies. The funding will be used to position the company as a leader in the filler market, which is the largest segment of the global non-invasive aesthetic market.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $7M |
| Last funding | $7M |
| Stage | A |
| Rounds | 2 |
| Investors | 2 |
Team Members
3
Employees: 11-50
Web & Social Links
| Website | www.hallura.com |
Locations
HaCarmel Street 67, Yokne'am Illit, Israel
Photos & Videos
No files yet
